| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| O Ruetsch, A Viala, H Bardou, P Martin, M N Vachero. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]. L'Encephale. vol 31. issue 4 Pt 1. 2006-02-24. PMID:16389718. |
the paper reviews actual epidemiological data concerning drug induced weight gain and associated health problems in psychiatric patients : there is a high risk of overweight, obesity, impaired glucose tolerance, diabetes mellitus, premature death, in patients with schizophrenia or bipolar disorder; and the effects of specific drugs on body weight: tricyclic antidepressants (tca) induced weight gain correlated positively with dosage and duration of treatment, more pronounced with amitriptyline ; selective serotonin reuptake inhibitors (ssri) decrease transiently bodyweight during the first few weeks of treatment and may then increase bodyweight; weight gain appears to be most prominent with some mood stabilizers (lithium, valproate); atypical antipsychotics tend to cause more weight gain than conventional ones and weight gain, diabetes, dyslipidemia, seem to be most severe with clozapine and olanzapine. |
2006-02-24 |
2023-08-12 |
Not clear |
| Harvey N Kranzler, Hana M Kester, Ginny Gerbino-Rosen, Inika N Henderson, Joseph Youngerman, Guy Beauzile, Keith Ditkowsky, Sanjiv Kumr. Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions. Child and adolescent psychiatric clinics of North America. vol 15. issue 1. 2006-02-15. PMID:16321728. |
treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions. |
2006-02-15 |
2023-08-12 |
Not clear |
| Branimir Margetić, Branka Aukst-Margetić, Anica Badanja. Importance of oral glucose tolerance test in patient with schizophrenia. Psychiatria Danubina. vol 17. issue 1-2. 2006-02-15. PMID:16395850. |
we describe the case of a 39-year-old patient with schizophrenia who developed worsening of glucose metabolism during treatment with two different atypical antipsychotics, clozapine and quetiapine. |
2006-02-15 |
2023-08-12 |
Not clear |
| Rajiv Tandon, W Wolfgang Fleischhacke. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophrenia research. vol 79. issue 2-3. 2006-02-14. PMID:16139989. |
data thus far do not support claims of differential efficacy among sgas with the singular exception of clozapine possibly still being the gold standard of antipsychotic efficacy in otherwise treatment-refractory schizophrenia. |
2006-02-14 |
2023-08-12 |
Not clear |
| Istvan Bitter, Pal Czobor, Martin Dossenbach, Jan Volavk. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). European psychiatry : the journal of the Association of European Psychiatrists. vol 20. issue 5-6. 2006-02-10. PMID:16084068. |
effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (ic-soho). |
2006-02-10 |
2023-08-12 |
Not clear |
| William G Honer, Allen E Thornton, Eric Y H Chen, Raymond C K Chan, Jessica O Y Wong, Andrea Bergmann, Peter Falkai, Edith Pomarol-Clotet, Peter J McKenna, Emmanuel Stip, Richard Williams, G William MacEwan, Kishor Wasan, Ric Procyshy. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. The New England journal of medicine. vol 354. issue 5. 2006-02-07. PMID:16452559. |
clozapine alone versus clozapine and risperidone with refractory schizophrenia. |
2006-02-07 |
2023-08-12 |
Not clear |
| Zhu Li, Mei Huang, Junji Ichikawa, Jin Dai, Herbert Y Meltze. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 11. 2006-01-24. PMID:15900318. |
previous studies have suggested that ndmc may be more important than the patent compound itself for the improvement in cognition in patients with schizophrenia treated with clozapine. |
2006-01-24 |
2023-08-12 |
rat |
| Zhu Li, Mei Huang, Junji Ichikawa, Jin Dai, Herbert Y Meltze. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 11. 2006-01-24. PMID:15900318. |
these findings suggest that: (1) ndmc is an m1 agonist while clozapine is an m1 antagonist in vivo; (2) m1 agonism of ndmc can contribute to the release of cortical ach and da release; (3) ndmc, because of its m1 agonism, may more effectively treat the cognitive impairments observed in schizophrenia than clozapine itself; and (4) m1 receptor agonism may be a valuable target for the development of drugs that can improve cognitive deficit in schizophrenia, and perhaps other neuropsychiatric disorders as well. |
2006-01-24 |
2023-08-12 |
rat |
| Ai-Ling Zhao, Jing-Ping Zhao, Yu-Hu Zhang, Zhi-Min Xue, Jin-Dong Chen, Xiao-Gang Che. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. The International journal of neuroscience. vol 115. issue 11. 2006-01-20. PMID:16223700. |
to investigate the relationship between 48 bp variant number tandem repeat polymorphism in dopamine d4 receptor gene and response to clozapine in schizophrenic patients, the authors included 81 inpatients with a dsm-iv diagnosis of schizophrenia and patients meeting criteria for refractory to treatment were excluded. |
2006-01-20 |
2023-08-12 |
Not clear |
| Marc Ziegenbein, Marcel Sieberer, Iris T Calliess, Stefan Krop. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. The Australian and New Zealand journal of psychiatry. vol 39. issue 9. 2006-01-11. PMID:16168043. |
combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. |
2006-01-11 |
2023-08-12 |
Not clear |
| Cherrie A Galletly, C Richard Clark, Alexander C McFarlan. Clozapine improves working memory updating in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 15. issue 6. 2006-01-05. PMID:15905072. |
clozapine improves working memory updating in schizophrenia. |
2006-01-05 |
2023-08-12 |
human |
| Cherrie A Galletly, C Richard Clark, Alexander C McFarlan. Clozapine improves working memory updating in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 15. issue 6. 2006-01-05. PMID:15905072. |
compared to matched controls and prior to treatment with clozapine, subjects with schizophrenia had n1, p3 and late slow wave abnormalities indicating impairment in early stimulus evaluation and subsequent working memory functions. |
2006-01-05 |
2023-08-12 |
human |
| Suresh Sundram, David Copolov, Brian Dea. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn-Schmiedeberg's archives of pharmacology. vol 371. issue 5. 2006-01-05. PMID:15995876. |
antipsychotic drugs are effective in the treatment of cannabis-induced psychosis, but only clozapine appears effective in the treatment of comorbid schizophrenia and cannabis use. |
2006-01-05 |
2023-08-12 |
rat |
| Suresh Sundram, David Copolov, Brian Dea. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn-Schmiedeberg's archives of pharmacology. vol 371. issue 5. 2006-01-05. PMID:15995876. |
if these results can be extrapolated into humans, then this effect of clozapine on the cb1 receptor may be a mechanism that makes it uniquely effective in schizophrenia and comorbid cannabis use. |
2006-01-05 |
2023-08-12 |
rat |
| Marc Ziegenbein, Stefan Kropp, Heike E Kuenze. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clinical neuropharmacology. vol 28. issue 5. 2006-01-05. PMID:16239761. |
combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. |
2006-01-05 |
2023-08-12 |
Not clear |
| Pablo Diaz, Sreenivasa Bhaskara, Serdar M Dursun, Bill Deaki. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. Journal of clinical psychopharmacology. vol 25. issue 3. 2005-12-30. PMID:15876911. |
double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. |
2005-12-30 |
2023-08-12 |
Not clear |
| Gary Remington, Amitabha Saha, Siow-Ann Chong, Chekkera Shamm. Augmentation strategies in clozapine-resistant schizophrenia. CNS drugs. vol 19. issue 10. 2005-12-07. PMID:16185094. |
the availability of other 'atypical' antipsychotics offers options, but clozapine appears to remain the most effective option in treatment-resistant schizophrenia. |
2005-12-07 |
2023-08-12 |
Not clear |
| Margaret A Niznikiewicz, Jayendra K Patel, Robert McCarley, Jonathan Sutton, David T Chau, Joanne Wojcik, Alan I Gree. Clozapine action on auditory P3 response in schizophrenia. Schizophrenia research. vol 76. issue 1. 2005-11-30. PMID:15927806. |
clozapine action on auditory p3 response in schizophrenia. |
2005-11-30 |
2023-08-12 |
Not clear |
| Jan Volavka, Karen A Nolan, Linda Kline, Pal Czobor, Leslie Citrome, Brian Sheitman, Jean-Pierre Lindenmayer, Joseph McEvoy, Jeffrey A Lieberma. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophrenia research. vol 76. issue 1. 2005-11-30. PMID:15927808. |
efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. |
2005-11-30 |
2023-08-12 |
Not clear |
| Roy H Perlis, David A Ganz, Jerry Avorn, Sebastian Schneeweiss, Robert J Glynn, Jordan W Smoller, Philip S Wan. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. Journal of clinical psychopharmacology. vol 25. issue 5. 2005-11-30. PMID:16160617. |
the identification of a putative genetic test for better clozapine response in schizophrenia offers an opportunity to evaluate the cost-effectiveness of such testing. |
2005-11-30 |
2023-08-12 |
Not clear |